中国肝移植受者选择与术前评估技术规范(2019版)

2020-01-10 中华医学会器官移植学分会 临床肝胆病杂志.2020.36(1):40-43.

肝移植作为各种类型不可逆急、慢性肝病的有效治疗手段,已被广泛接受。经过几十年稳步持续的发展,肝移植技术逐渐成熟。随着肝移植技术的发展、新型免疫抑制剂的应用以及围手术期管理的进步,肝移植适应证和禁忌证也在发生变化。详细的术前检查和准备是保证肝移植预后的重要环节。为进一步规范我国肝移植受者选择以及术前评估和准备,中华医学会器官移植学分会组织肝移植专家,总结国内外相关研究最新进展,结合国际指南和临床实践

中文标题:

中国肝移植受者选择与术前评估技术规范(2019版)

发布日期:

2020-01-10

简要介绍:

肝移植作为各种类型不可逆急、慢性肝病的有效治疗手段,已被广泛接受。经过几十年稳步持续的发展,肝移植技术逐渐成熟。随着肝移植技术的发展、新型免疫抑制剂的应用以及围手术期管理的进步,肝移植适应证和禁忌证也在发生变化。详细的术前检查和准备是保证肝移植预后的重要环节。为进一步规范我国肝移植受者选择以及术前评估和准备,中华医学会器官移植学分会组织肝移植专家,总结国内外相关研究最新进展,结合国际指南和临床实践,从肝移植适应证和禁忌证、受者术前检查、术前准备以及常见并发症处理等方面,制订《中国肝移植受者选择与术前评估技术规范(2019 版)》。

 

拓展指南:肝移植相关指南:

下载附件:

(因为版权问题,不支持下载)

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=920266, encodeId=2aaf92026654, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=750f5456420, createdName=ms5000000625261973, createdTime=Wed Jan 27 11:54:55 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906041, encodeId=e8c59060417f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:48:13 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809735, encodeId=c938809e35dd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Aug 17 16:56:51 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809334, encodeId=8684809334bc, content=很喜欢的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Aug 16 11:37:48 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2021-01-27 ms5000000625261973

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=920266, encodeId=2aaf92026654, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=750f5456420, createdName=ms5000000625261973, createdTime=Wed Jan 27 11:54:55 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906041, encodeId=e8c59060417f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:48:13 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809735, encodeId=c938809e35dd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Aug 17 16:56:51 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809334, encodeId=8684809334bc, content=很喜欢的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Aug 16 11:37:48 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-12-08 14861974m47(暂无昵称)

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=920266, encodeId=2aaf92026654, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=750f5456420, createdName=ms5000000625261973, createdTime=Wed Jan 27 11:54:55 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906041, encodeId=e8c59060417f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:48:13 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809735, encodeId=c938809e35dd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Aug 17 16:56:51 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809334, encodeId=8684809334bc, content=很喜欢的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Aug 16 11:37:48 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-08-17 ms4000001617780766

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=920266, encodeId=2aaf92026654, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=750f5456420, createdName=ms5000000625261973, createdTime=Wed Jan 27 11:54:55 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906041, encodeId=e8c59060417f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b3d5290623, createdName=14861974m47(暂无昵称), createdTime=Tue Dec 08 15:48:13 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809735, encodeId=c938809e35dd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Aug 17 16:56:51 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809334, encodeId=8684809334bc, content=很喜欢的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Aug 16 11:37:48 CST 2020, time=2020-08-16, status=1, ipAttribution=)]
    2020-08-16 ms1000000302953060

    很喜欢的指南

    0